Drugs / attIL2-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05621668 | Sep 2023 → Sep 2027 expected | bone sarcoma, soft tissue sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | attIL2-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05621668 ↗ |
| Modality | Cell therapy | “T-Cell Therapy” NCT05621668 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT05621668 ↗ |